Mouse IgG2a Isotype Therapeutic Antibodies Elicit Superior Tumor Growth Control Compared with mIgG1 or mIgE

In the last decades, antibody-based tumor therapy has fundamentally improved the efficacy of treatment for patients with cancer. Currently, almost all tumor antigen–targeting antibodies approved for clinical application are of IgG1 Fc isotype. Similarly, the mouse homolog mIgG2a is the most commonly...

Descripción completa

Detalles Bibliográficos
Autores principales: Vukovic, Natasa, Segués, Aina, Huang, Shuyu, Waterfall, Martin, Sijts, Alice J.A.M., Zaiss, Dietmar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035513/
https://www.ncbi.nlm.nih.gov/pubmed/36968226
http://dx.doi.org/10.1158/2767-9764.CRC-22-0356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035513/
https://www.ncbi.nlm.nih.gov/pubmed/36968226
http://dx.doi.org/10.1158/2767-9764.CRC-22-0356

Ejemplares similares